These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 33711470)

  • 1. Targeting strategies of oral nano-delivery systems for treating inflammatory bowel disease.
    Liu W; Dong Z; Liu K; Lu Y; Wu W; Qi J; Chen Z
    Int J Pharm; 2021 May; 600():120461. PubMed ID: 33711470
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advances in oral nano-delivery systems for colon targeted drug delivery in inflammatory bowel disease: selective targeting to diseased versus healthy tissue.
    Hua S; Marks E; Schneider JJ; Keely S
    Nanomedicine; 2015 Jul; 11(5):1117-32. PubMed ID: 25784453
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nanoparticle-Mediated Drug Delivery Systems For The Treatment Of IBD: Current Perspectives.
    Yang C; Merlin D
    Int J Nanomedicine; 2019; 14():8875-8889. PubMed ID: 32009785
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug delivery strategies in the therapy of inflammatory bowel disease.
    Lautenschläger C; Schmidt C; Fischer D; Stallmach A
    Adv Drug Deliv Rev; 2014 May; 71():58-76. PubMed ID: 24157534
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Orally-administered nanomedicine systems targeting colon inflammation for the treatment of inflammatory bowel disease: latest advances.
    Hu S; Zhao R; Xu Y; Gu Z; Zhu B; Hu J
    J Mater Chem B; 2023 Dec; 12(1):13-38. PubMed ID: 38018424
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral colon-specific therapeutic approaches toward treatment of inflammatory bowel disease.
    Xiao B; Merlin D
    Expert Opin Drug Deliv; 2012 Nov; 9(11):1393-407. PubMed ID: 23036075
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stimulus-responsive drug delivery nanoplatforms for inflammatory bowel disease therapy.
    Long J; Liang X; Ao Z; Tang X; Li C; Yan K; Yu X; Wan Y; Li Y; Li C; Zhou M
    Acta Biomater; 2024 Oct; 188():27-47. PubMed ID: 39265673
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advances in Pharmaceutical Strategies Enhancing the Efficiencies of Oral Colon-Targeted Delivery Systems in Inflammatory Bowel Disease.
    Guo Y; Zong S; Pu Y; Xu B; Zhang T; Wang B
    Molecules; 2018 Jul; 23(7):. PubMed ID: 29973488
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nanoparticles for oral delivery: targeted therapy for inflammatory bowel disease.
    Li DF; Yang MF; Xu HM; Zhu MZ; Zhang Y; Tian CM; Nie YQ; Wang JY; Liang YJ; Yao J; Wang LS
    J Mater Chem B; 2022 Aug; 10(31):5853-5872. PubMed ID: 35876136
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Size-dependent nanoparticulate drug delivery in inflammatory bowel diseases.
    Youshia J; Lamprecht A
    Expert Opin Drug Deliv; 2016; 13(2):281-94. PubMed ID: 26637060
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New Insights of Oral Colonic Drug Delivery Systems for Inflammatory Bowel Disease Therapy.
    Teruel AH; Gonzalez-Alvarez I; Bermejo M; Merino V; Marcos MD; Sancenon F; Gonzalez-Alvarez M; Martinez-Mañez R
    Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32899548
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral delivery of micro/nanoparticulate systems based on natural polysaccharides for intestinal diseases therapy: Challenges, advances and future perspectives.
    Dos Santos AM; Carvalho SG; Meneguin AB; Sábio RM; Gremião MPD; Chorilli M
    J Control Release; 2021 Jun; 334():353-366. PubMed ID: 33901582
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Application of chitosan as nano carrier in the treatment of inflammatory bowel disease.
    Liu X; Dong Y; Wang C; Guo Z
    Int J Biol Macromol; 2024 Oct; 278(Pt 4):134899. PubMed ID: 39187100
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The application of natural product-delivering micro/nano systems in the treatment of inflammatory bowel disease.
    Zhou Y; Feng X; Xu H; Guo J; Yang C; Kong L; Zhang Z
    J Mater Chem B; 2023 Jan; 11(2):244-260. PubMed ID: 36512384
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mesopore to Macropore Transformation of Metal-Organic Framework for Drug Delivery in Inflammatory Bowel Disease.
    Yin Y; Yang J; Pan Y; Gao Y; Huang L; Luan X; Lin Z; Zhu W; Li Y; Song Y
    Adv Healthc Mater; 2021 Feb; 10(3):e2000973. PubMed ID: 33369176
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New targeting strategies in drug therapy of inflammatory bowel disease: mechanistic approaches and opportunities.
    Wolk O; Epstein S; Ioffe-Dahan V; Ben-Shabat S; Dahan A
    Expert Opin Drug Deliv; 2013 Sep; 10(9):1275-86. PubMed ID: 23721560
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exploiting disease-induced changes for targeted oral delivery of biologics and nanomedicines in inflammatory bowel disease.
    Zhang Y; Thanou M; Vllasaliu D
    Eur J Pharm Biopharm; 2020 Oct; 155():128-138. PubMed ID: 32853696
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pathological features-based targeted delivery strategies in IBD therapy: A mini review.
    Li S; Zhang F; Zhang Q
    Biomed Pharmacother; 2022 Jul; 151():113079. PubMed ID: 35605297
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Drug delivery strategies for targeted treatment of inflammatory bowel disease].
    Lautenschläger C; Schmidt C; Lange K; Stallmach A
    Z Gastroenterol; 2015 Mar; 53(3):226-34. PubMed ID: 25723326
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel drug delivery strategies for the treatment of inflammatory bowel disease.
    Kesisoglou F; Zimmermann EM
    Expert Opin Drug Deliv; 2005 May; 2(3):451-63. PubMed ID: 16296767
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.